GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
发明人:
BARBASH, OLENA,FEDORIW, ANDY,KORENCHUK, SUSAN,MOHAMMAD, HELAI,SHERK, CHRISTIAN
申请号：
CA3045241
公开号：
CA3045241A1
申请日:
2017.11.30
申请国别(地区):
CA
年份:
2018
代理人:
摘要：
In one embodiment, the present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and an immuno-modulatory agent selected from: an anti-PD-1 antibody or antigen binding fragment thereof, an anti-PDL1 antibody or antigen binding fragment thereof, and an anti-OX40 antibody or antigen binding fragment thereof. In another embodiment, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of an immuno-modulatory agent selected from: an anti-PD-1 antibody or antigen binding fragment thereof, an anti-PDL1 antibody or antigen binding fragment thereof, and an anti-OX40 antibody or antigen binding fragment thereof. In another embodiment, methods for treating cancer in a human in need thereof are provided, the methods comprising administering to the human the combinations or pharmaceutical compositions provided herein.
